<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926805</url>
  </required_header>
  <id_info>
    <org_study_id>CIA-279</org_study_id>
    <secondary_id>U1111-1259-4797</secondary_id>
    <nct_id>NCT04926805</nct_id>
  </id_info>
  <brief_title>Physiological Study to Compare Noninvasive Ventilation (NIV) Masks</brief_title>
  <official_title>Physiological Study to Compare Noninvasive Ventilation (NIV) Masks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisher and Paykel Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fisher and Paykel Healthcare</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Noninvasive ventilation (NIV) is an established therapy that delivers positive pressure to&#xD;
      the upper airways to provide respiratory support. Two types of NIV can be delivered;&#xD;
      continuous positive airway pressure (CPAP) at one continuous pressure and bilevel NIV at two&#xD;
      pressures for inhalation and exhalation.&#xD;
&#xD;
      This investigation is designed to physiologically evaluate the performance of a NIV mask,&#xD;
      Mask A, compared to a standard NIV mask, Mask B on CPAP therapy.&#xD;
&#xD;
      People with sleep disordered breathing who have chronic hypercapnia, and are already&#xD;
      receiving nocturnal CPAP will be recruited. They will receive one night's CPAP therapy on&#xD;
      Mask A and 1 night on Mask B in random order. Physiological parameters will be recorded.&#xD;
&#xD;
      Parameters will be recorded during three baselines at the beginning of each evening and&#xD;
      throughout the night when participants are asleep. The three baselines are:&#xD;
&#xD;
        1. participant awake with normal breathing (not on CPAP),&#xD;
&#xD;
        2. participant awake and on CPAP, and&#xD;
&#xD;
        3. participant asleep on CPAP in REM-sleep (rapid eye movement sleep).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transcutaneous carbon dioxide</measure>
    <time_frame>1 day (From baseline to the end of the study night)</time_frame>
    <description>The change in transcutaneous carbon dioxide from the 3 different baselines to the transcutaneous carbon dioxide during non-REM sleep on CPAP on the same study night. Three different values will be determined for each mask.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sleep-disordered Breathing</condition>
  <condition>Hypercapnia</condition>
  <arm_group>
    <arm_group_label>Mask A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overnight CPAP using the participant's usual pressure settings and using Mask A. One night only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mask B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Overnight CPAP using the participant's usual pressure settings and using Mask B. One night only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP with Mask A</intervention_name>
    <description>CPAP mask</description>
    <arm_group_label>Mask A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP with Mask B</intervention_name>
    <description>CPAP mask</description>
    <arm_group_label>Mask B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Already using overnight CPAP and tolerating the therapy well (over 4 hours use/night)&#xD;
&#xD;
          -  Hypercapnia: venous bicarbonate of 30 milliequivalents of solute per liter (Eq/L) or&#xD;
             more, OR transcutaneous carbon dioxide (TcCO2) of 50 millimeters of mercury (mmHg) of&#xD;
             more.&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Already use a full (oronasal) face mask for CPAP&#xD;
&#xD;
          -  Willing to have a venous blood sample taken during the pre-screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of sleep apnea on CPAP:&#xD;
&#xD;
               -  Subjects excluded if they have an apnea-hypopnea index (AHI) of more than 20, or&#xD;
&#xD;
               -  If the AHI has not already decreased by 50 percent or more from pre-CPAP to with&#xD;
                  CPAP.&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) of less than 40 percent of predicted.&#xD;
&#xD;
          -  Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC) less&#xD;
             than fifty percent of predicted, at the screening visit.&#xD;
&#xD;
               -  Have poorly controlled asthma or changing asthma symptoms.&#xD;
&#xD;
               -  Nasal obstruction&#xD;
&#xD;
               -  Do not fit Mask A or Mask B&#xD;
&#xD;
               -  Agitation or psychological illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andy Veale, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Zealand Respiratory and Sleep Insitute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Zealand Respiratory and Sleep Institute</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

